{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:27:14Z","timestamp":1793935634532,"version":"4.8.0"},"reference-count":136,"publisher":"Oxford University Press (OUP)","issue":"16","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,21]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anderson\u2013Fabry disease (AFD) is a lysosomal storage disorder characterized by glycolipid accumulation in cardiac cells, associated with a peculiar form of hypertrophic cardiomyopathy (HCM). Up to 1% of patients with a diagnosis of HCM indeed have AFD. With the availability of targeted therapies for sarcomeric HCM and its genocopies, a timely differential diagnosis is essential. Specifically, the therapeutic landscape for AFD is rapidly evolving and offers increasingly effective, disease-modifying treatment options. However, diagnosing AFD may be difficult, particularly in the non-classic phenotype with prominent or isolated cardiac involvement and no systemic red flags. For many AFD patients, the clinical journey from initial clinical manifestations to diagnosis and appropriate treatment remains challenging, due to late recognition or utter neglect. Consequently, late initiation of treatment results in an exacerbation of cardiac involvement, representing the main cause of morbidity and mortality, irrespective of gender. Optimal management of AFD patients requires a dedicated multidisciplinary team, in which the cardiologist plays a decisive role, ranging from the differential diagnosis to the prevention of complications and the evaluation of timing for disease-specific therapies. The present review aims to redefine the role of cardiologists across the main decision nodes in contemporary AFD clinical care and drug discovery.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehae148","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T05:06:33Z","timestamp":1710479193000},"page":"1395-1409","source":"Crossref","is-referenced-by-count":63,"title":["Anderson\u2013Fabry disease management: role of the cardiologist"],"prefix":"10.1093","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6830-4292","authenticated-orcid":false,"given":"Maurizio","family":"Pieroni","sequence":"first","affiliation":[{"name":"Cardiovascular Department, San Donato Hospital , Via Pietro Nenni 22, 52100 Arezzo , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Namdar","sequence":"additional","affiliation":[{"name":"Cardiology Division, H\u00f4pitaux Universitaires de Gen\u00e8ve , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1751-9266","authenticated-orcid":false,"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi Hospital and Meyer Children\u2019s Hospital IRCCS , Florence , Italy"},{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Desnick","sequence":"additional","affiliation":[{"name":"Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"2024042116171078000_ehae148-B1","first-page":"3733","volume-title":"The Metabolic and Molecular Basis of Inherited Disease","author":"Desnick","year":"2001","edition":"8th ed"},{"key":"2024042116171078000_ehae148-B2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2024042116171078000_ehae148-B3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis"},{"key":"2024042116171078000_ehae148-B4","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"key":"2024042116171078000_ehae148-B5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac involvement in Fabry disease. JACC review topic of the week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024042116171078000_ehae148-B6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","article-title":"Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995\u20132017","volume":"55","author":"Doheny","year":"2018","journal-title":"J Med Genet"},{"key":"2024042116171078000_ehae148-B7","doi-asserted-by":"crossref","first-page":"e024656","DOI":"10.1161\/JAHA.121.024656","article-title":"Cardiac myosin inhibitors as a novel treatment option for obstructive hypertrophic cardiomyopathy: addressing the core of the matter","volume":"11","author":"Masri","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2024042116171078000_ehae148-B8","doi-asserted-by":"crossref","first-page":"e010687","DOI":"10.1161\/CIRCHEARTFAILURE.123.010687","article-title":"Targeted therapies in pediatric and adult patients with hypertrophic heart disease: from molecular pathophysiology to personalized medicine","volume":"16","author":"Monda","year":"2023","journal-title":"Circ Heart Fail"},{"key":"2024042116171078000_ehae148-B9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: data from the Fabry Registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J Med Genet"},{"key":"2024042116171078000_ehae148-B10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jchf.2023.09.015","article-title":"Applications of gene therapy in cardiomyopathies","volume":"12","author":"Argiro","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2024042116171078000_ehae148-B11","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2024042116171078000_ehae148-B12","doi-asserted-by":"crossref","first-page":"e0244279","DOI":"10.1371\/journal.pone.0244279","article-title":"The patient journey of patients with Fabry disease, Gaucher disease and mucopolysaccharidosis type II: a German-wide telephone survey","volume":"15","author":"Mengel","year":"2020","journal-title":"PLoS One"},{"key":"2024042116171078000_ehae148-B13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13023-022-02517-0","article-title":"Rare lysosomal disease registries: lessons learned over three decades of real-world evidence","volume":"17","author":"Mistry","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2024042116171078000_ehae148-B14","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2024042116171078000_ehae148-B15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/mgg3.389","article-title":"Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry Registry study","volume":"6","author":"Germain","year":"2018","journal-title":"Mol Genet Genomic Med"},{"key":"2024042116171078000_ehae148-B16","doi-asserted-by":"crossref","first-page":"e0193550","DOI":"10.1371\/journal.pone.0193550","article-title":"Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation","volume":"13","author":"Lavalle","year":"2018","journal-title":"PLoS One"},{"key":"2024042116171078000_ehae148-B17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ymgme.2019.07.012","article-title":"Founder effect of Fabry disease due to p.F113L mutation: clinical profile of a late-onset phenotype","volume":"129","author":"Azevedo","year":"2020","journal-title":"Mol Genet Metab"},{"key":"2024042116171078000_ehae148-B18","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","article-title":"Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation","volume":"68","author":"Hsu","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2024042116171078000_ehae148-B19","doi-asserted-by":"crossref","first-page":"e004252","DOI":"10.1161\/CIRCGEN.123.004252","article-title":"Impact of GLA variant classification on the estimated prevalence of Fabry disease: a systematic review and meta-analysis of screening studies","volume":"16","author":"Monda","year":"2023","journal-title":"Circ Genom Precis Med"},{"key":"2024042116171078000_ehae148-B20","doi-asserted-by":"crossref","first-page":"e2029","DOI":"10.1002\/mgg3.2029","article-title":"X-chromosomal inactivation patterns in women with Fabry disease","volume":"10","author":"Wagenh\u00e4user","year":"2022","journal-title":"Mol Genet Genomic Med"},{"key":"2024042116171078000_ehae148-B21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ymgme.2017.07.012","article-title":"The role of epigenetics in lysosomal storage disorders: uncharted territory","volume":"122","author":"Hassan","year":"2017","journal-title":"Mol Genet Metab"},{"key":"2024042116171078000_ehae148-B22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10545-017-0098-3","article-title":"Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy","volume":"41","author":"Burlina","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"2024042116171078000_ehae148-B23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","article-title":"Newborn screening for lysosomal storage disorders in Illinois: the initial 15-month experience","volume":"190","author":"Burton","year":"2017","journal-title":"J Pediatr"},{"key":"2024042116171078000_ehae148-B24","doi-asserted-by":"crossref","first-page":"1152568","DOI":"10.3389\/fcvm.2023.1152568","article-title":"Anderson-Fabry disease cardiomyopathy: an update on epidemiology, diagnostic approach, management and monitoring strategies","volume":"10","author":"Averbuch","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2024042116171078000_ehae148-B25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/jmg-2022-108523","article-title":"Prevalence of Fabry disease-causing variants in the UK Biobank","volume":"60","author":"Gilchrist","year":"2023","journal-title":"J Med Genet"},{"key":"2024042116171078000_ehae148-B26","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"2024042116171078000_ehae148-B27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"2024042116171078000_ehae148-B28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"2024042116171078000_ehae148-B29","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"2024042116171078000_ehae148-B30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"key":"2024042116171078000_ehae148-B31","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","article-title":"Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice","volume":"51","author":"Sakuraba","year":"2006","journal-title":"J Hum Genet"},{"key":"2024042116171078000_ehae148-B32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ymgme.2013.12.296","article-title":"Comparative study on mannose 6-phosphate residue contents of recombinant lysosomal enzymes","volume":"111","author":"Togawa","year":"2014","journal-title":"Mol Genet Metab"},{"key":"2024042116171078000_ehae148-B33","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1681\/ASN.2018070740","article-title":"Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2024042116171078000_ehae148-B34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1136\/jmedgenet-2020-106874","article-title":"Treatment switch in Fabry disease\u2014a matter of dose?","volume":"58","author":"Lenders","year":"2021","journal-title":"J Med Genet"},{"key":"2024042116171078000_ehae148-B35","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ymgme.2022.10.005","article-title":"Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues","volume":"137","author":"T\u00f8ndel","year":"2022","journal-title":"Mol Genet Metab"},{"key":"2024042116171078000_ehae148-B36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000448968","article-title":"Long term treatment with enzyme replacement therapy in patients with Fabry disease","volume":"134","author":"Oder","year":"2016","journal-title":"Nephron"},{"key":"2024042116171078000_ehae148-B37","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","article-title":"Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease","volume":"121","author":"Arends","year":"2017","journal-title":"Mol Genet Metab"},{"key":"2024042116171078000_ehae148-B38","doi-asserted-by":"crossref","first-page":"100454","DOI":"10.1016\/j.ymgmr.2019.100454","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol Genet Metab Rep"},{"key":"2024042116171078000_ehae148-B39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"T\u00f8ndel","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2024042116171078000_ehae148-B40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cge.13546","article-title":"Consensus recommendations for diagnosis management and treatment of Fabry disease in paediatric patients","volume":"96","author":"Germain","year":"2019","journal-title":"Clin Genet"},{"key":"2024042116171078000_ehae148-B41","doi-asserted-by":"crossref","first-page":"106967","DOI":"10.1016\/j.ymgme.2022.106967","article-title":"Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: an analysis from the Fabry Registry","volume":"138","author":"Hopkin","year":"2022","journal-title":"Mol Genet Metab"},{"key":"2024042116171078000_ehae148-B42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2021.12.004","article-title":"Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression","volume":"135","author":"van der Veen","year":"2022","journal-title":"Mol Genet Metab"},{"key":"2024042116171078000_ehae148-B43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ymgme.2020.04.003","article-title":"Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: phase I and II\/III clinical studies","volume":"130","author":"Nakamura","year":"2020","journal-title":"Mol Genet Metab"},{"key":"2024042116171078000_ehae148-B44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40268-023-00421-x","article-title":"Development of a biosimilar of agalsidase beta for the treatment of Fabry disease: preclinical evaluation","volume":"23","author":"van Kuilenburg","year":"2023","journal-title":"Drugs R D"},{"key":"2024042116171078000_ehae148-B45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","article-title":"Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year phase1\/2 clinical trial","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J Inherit Metab Dis"},{"key":"2024042116171078000_ehae148-B46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat Med"},{"key":"2024042116171078000_ehae148-B47","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bbadis.2004.07.001","article-title":"Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease","volume":"1690","author":"Ishii","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"2024042116171078000_ehae148-B48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/mt.2009.220","article-title":"The pharmacological chaperone 1-deoxygalactonojirimcin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease","volume":"18","author":"Khanna","year":"2010","journal-title":"Mol Ther"},{"key":"2024042116171078000_ehae148-B49","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med"},{"key":"2024042116171078000_ehae148-B50","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"key":"2024042116171078000_ehae148-B51","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-monthe results from the randomized phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med Genet"},{"key":"2024042116171078000_ehae148-B52","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41436-019-0451-z","article-title":"Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study","volume":"21","author":"Germain","year":"2019","journal-title":"Genet Med"},{"key":"2024042116171078000_ehae148-B53","doi-asserted-by":"crossref","first-page":"106981","DOI":"10.1016\/j.ymgme.2022.106981","article-title":"Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: a prospective, multicenter study","volume":"138","author":"Mu\u0308ntze","year":"2023","journal-title":"Mol Genet Metab"},{"key":"2024042116171078000_ehae148-B54","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/cpt.1536","article-title":"Oral chaperone therapy migalastat for the treatment of Fabry disease: potentials and pitfalls of real-world data","volume":"106","author":"K\u00f6rver","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2024042116171078000_ehae148-B55","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.1832","article-title":"Treatment of Fabry\u2019s disease with migalastat: outcome from a prospective observational multicenter study","volume":"108","author":"Lenders","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2024042116171078000_ehae148-B56","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmedgenet-2019-106005","article-title":"Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy","volume":"56","author":"Lenders","year":"2019","journal-title":"J Med Genet"},{"key":"2024042116171078000_ehae148-B57","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/ijms21030956","article-title":"Assessment of gene variant amenability for pharmacological chaperone therapy with 1-deoxygalactonojirimycin in Fabry disease","volume":"21","author":"Lukas","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2024042116171078000_ehae148-B58","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ymgme.2019.04.005","article-title":"Inter-assay variability influences migalastat amenability assessment among Fabry disease variants","volume":"127","author":"Oommen","year":"2019","journal-title":"Mol Gene Metab"},{"key":"2024042116171078000_ehae148-B59","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","article-title":"Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement","volume":"103","author":"Guerard","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2024042116171078000_ehae148-B60","doi-asserted-by":"crossref","first-page":"106963","DOI":"10.1016\/j.ymgme.2022.11.002","article-title":"Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study","volume":"138","author":"Deegan","year":"2023","journal-title":"Mol Genet Metab"},{"key":"2024042116171078000_ehae148-B61","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3390\/pharmaceutics15071936","article-title":"Novel golden lipid nanoparticles with small interference ribonucleic acid for substrate reduction therapy in Fabry disease","volume":"15","author":"Beraza-Millor","year":"2023","journal-title":"Pharmaceutics"},{"key":"2024042116171078000_ehae148-B62","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systematic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am J Hum Genet"},{"key":"2024042116171078000_ehae148-B63","doi-asserted-by":"crossref","DOI":"10.1177\/09636897231173734","article-title":"In vivo delivery of therapeutic molecules by transplantation of genome-edited induced pluripotent stem cells","volume":"32","author":"Nakajima","year":"2023","journal-title":"Cell Transplant"},{"key":"2024042116171078000_ehae148-B64","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1073\/pnas.061020598","article-title":"Preselective gene therapy for Fabry disease","volume":"98","author":"Qin","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024042116171078000_ehae148-B65","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.mt.6300066","article-title":"Correction of the biochemical and functional deficits in Fabry mice following AA8-mediated hepatic expression of alpha-galactosidase A","volume":"15","author":"Ziegler","year":"2007","journal-title":"Mol Ther"},{"key":"2024042116171078000_ehae148-B66","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41434-022-00381-y","article-title":"Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease","volume":"30","author":"Jeyakumar","year":"2023","journal-title":"Gene Ther"},{"key":"2024042116171078000_ehae148-B67","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.omtm.2020.07.002","article-title":"AAV2\/6 gene therapy in a murine model of Fabry disease results in supraphysiological enzyme activity and effective substrate reduction","volume":"18","author":"Yasuda","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024042116171078000_ehae148-B68","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.gt.3302839","article-title":"Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem\/progenitor cells","volume":"14","author":"Yoshimitsu","year":"2007","journal-title":"Gene Ther"},{"key":"2024042116171078000_ehae148-B69","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.omtm.2023.01.003","article-title":"Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease","volume":"28","author":"Saleh","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024042116171078000_ehae148-B70","author":"Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1\/2 STAAR Study in Fabry Disease"},{"key":"2024042116171078000_ehae148-B71","doi-asserted-by":"crossref","first-page":"196","DOI":"10.31083\/j.rcm2306196","article-title":"The heart in Fabry disease: mechanisms beyond storage and forthcoming therapies","volume":"23","author":"Pieroni","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"2024042116171078000_ehae148-B72","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jcmg.2023.06.011","article-title":"Correlations between cardiac magnetic resonance and myocardial histologic findings in Fabry disease","volume":"16","author":"Ditaranto","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"2024042116171078000_ehae148-B73","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.2353\/ajpath.2008.070576","article-title":"Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease","volume":"172","author":"Chimenti","year":"2008","journal-title":"Am J Pathol"},{"key":"2024042116171078000_ehae148-B74","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3390\/jcm9041116","article-title":"Altered sphingolipids metabolism damaged mitochondrial functions: lessons learned from Gaucher and Fabry diseases","volume":"9","author":"Ivanova","year":"2020","journal-title":"J Clin Med"},{"key":"2024042116171078000_ehae148-B75","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.122.001250","article-title":"Mitochondrial microRNAs are dysregulated in patients with Fabry disease","volume":"384","author":"Gambardella","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"2024042116171078000_ehae148-B76","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.stemcr.2019.07.004","article-title":"A human stem cell model of Fabry disease implicates LIMP-2 accumulation in cardiomyocyte pathology","volume":"13","author":"Birket","year":"2019","journal-title":"Stem Cell Reports"},{"key":"2024042116171078000_ehae148-B77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fcvm.2016.00007","article-title":"Electrocardiographic changes and arrhythmia in Fabry disease","volume":"3","author":"Namdar","year":"2016","journal-title":"Front Cardiovasc Med"},{"key":"2024042116171078000_ehae148-B78","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol Genet Metab"},{"key":"2024042116171078000_ehae148-B79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/8904_2014_371","article-title":"Innate and adaptive immune response in Fabry disease","volume":"22","author":"Mauhin","year":"2015","journal-title":"JIMD Rep"},{"key":"2024042116171078000_ehae148-B80","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","article-title":"Lyso-Gb3 activates Notch1 in human podocytes","volume":"24","author":"Sanchez-Ni\u00f1o","year":"2015","journal-title":"Hum Mol Genet"},{"key":"2024042116171078000_ehae148-B81","doi-asserted-by":"crossref","first-page":"e009098","DOI":"10.1161\/JAHA.118.009098","article-title":"Elevated inflammatory plasma biomarkers in patients with Fabry disease: a critical link to heart failure with preserved ejection fraction","volume":"7","author":"Yogasundaram","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2024042116171078000_ehae148-B82","doi-asserted-by":"crossref","first-page":"e009430","DOI":"10.1161\/CIRCIMAGING.119.009430","article-title":"Myocardial storage, inflammation, and cardiac phenotype in Fabry disease after one year of enzyme replacement therapy","volume":"12","author":"Nordin","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"2024042116171078000_ehae148-B83","doi-asserted-by":"crossref","first-page":"e009052","DOI":"10.1161\/JAHA.118.009052","article-title":"Immune-mediated myocarditis in Fabry disease cardiomyopathy","volume":"7","author":"Frustaci","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2024042116171078000_ehae148-B84","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ehjci\/jeaa101","article-title":"The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage","volume":"22","author":"Augusto","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2024042116171078000_ehae148-B85","doi-asserted-by":"crossref","first-page":"e010171","DOI":"10.1161\/CIRCIMAGING.119.010171","article-title":"Myocardial edema, myocyte injury, and disease severity in Fabry disease","volume":"13","author":"Augusto","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"2024042116171078000_ehae148-B86","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s11886-022-01778-2","article-title":"Beyond sarcomeric hypertrophic cardiomyopathy: how to diagnose and manage phenocopies","volume":"24","author":"Pieroni","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"2024042116171078000_ehae148-B87","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1002\/ehf2.14091","article-title":"Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations","volume":"9","author":"Rob","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2024042116171078000_ehae148-B88","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jcmg.2018.11.039","article-title":"The role of cardiac imaging in the diagnosis and management of Anderson-Fabry disease","volume":"12","author":"Perry","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2024042116171078000_ehae148-B89","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ehf2.13101","article-title":"Evidence of evolution towards left midventricular obstruction in severe Anderson-Fabry cardiomyopathy","volume":"8","author":"Graziani","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2024042116171078000_ehae148-B90","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jcmg.2022.03.004","article-title":"Coronary microvascular dysfunction is associated with a worse cardiac phenotype in patients with Fabry disease","volume":"15","author":"Graziani","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"2024042116171078000_ehae148-B91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijcard.2022.07.046","article-title":"Myocardial infarction with non-obstructive coronary arteries in hypertrophic cardiomyopathy vs Fabry disease","volume":"369","author":"Graziani","year":"2022","journal-title":"Int J Cardiol"},{"key":"2024042116171078000_ehae148-B92","doi-asserted-by":"crossref","first-page":"f153","DOI":"10.1093\/europace\/eux261","article-title":"Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice","volume":"20","author":"Baig","year":"2018","journal-title":"Europace"},{"key":"2024042116171078000_ehae148-B93","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.jcmg.2020.05.011","article-title":"Atrial dysfunction assessed by cardiac magnetic resonance as an early marker of Fabry cardiomyopathy","volume":"13","author":"Bernardini","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2024042116171078000_ehae148-B94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ijcp.12914","article-title":"Time delays in the diagnosis and treatment of Fabry disease","volume":"71","author":"Reisin","year":"2017","journal-title":"Int J Clin Pract"},{"key":"2024042116171078000_ehae148-B95","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/eurheartj\/ehs397","article-title":"Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"2024042116171078000_ehae148-B96","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijcard.2019.06.073","article-title":"Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy","volume":"299","author":"Limongelli","year":"2020","journal-title":"Int J Cardiol"},{"key":"2024042116171078000_ehae148-B97","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/eurheartj\/ehac764","article-title":"Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments","volume":"44","author":"Olivotto","year":"2023","journal-title":"Eur Heart J"},{"key":"2024042116171078000_ehae148-B98","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijcard.2021.06.032","article-title":"Recognition of pre-hypertrophic cardiac involvement in Fabry disease based on automated electrocardiographic measures","volume":"338","author":"Namdar","year":"2021","journal-title":"Int J Cardiol"},{"key":"2024042116171078000_ehae148-B99","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ehjci\/jead121","article-title":"Three-dimensional echocardiographic left ventricular strain analysis in Fabry disease: correlation with heart failure severity, myocardial scar, and impact on long-term prognosis","volume":"24","author":"Marek","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2024042116171078000_ehae148-B100","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jacc.2023.07.026","article-title":"Prognostic implications of the extent of cardiac damage in patients with Fabry disease","volume":"82","author":"Meucci","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024042116171078000_ehae148-B101","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jcmg.2018.03.020","article-title":"Proposed stages of myocardial phenotype development in Fabry disease","volume":"12","author":"Nordin","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2024042116171078000_ehae148-B102","doi-asserted-by":"crossref","first-page":"e008424","DOI":"10.1161\/CIRCIMAGING.118.008424","article-title":"Predictors of clinical evolution in prehypertrophic Fabry disease","volume":"12","author":"Camporeale","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"2024042116171078000_ehae148-B103","doi-asserted-by":"crossref","DOI":"10.1007\/s10741-023-10370-x","article-title":"Clinical staging of Anderson-Fabry cardiomyopathy: an operative proposal","author":"Del Franco","year":"2023","journal-title":"Heart Fail Rev"},{"key":"2024042116171078000_ehae148-B104","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.3346\/jkms.2019.34.e63","article-title":"Prevalence of Fabry disease in Korean men with left ventricular hypertrophy","volume":"34","author":"Kim","year":"2019","journal-title":"J Korean Med Sci"},{"key":"2024042116171078000_ehae148-B105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10545-013-9659-2","article-title":"Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS)","volume":"37","author":"Palecek","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"2024042116171078000_ehae148-B106","doi-asserted-by":"crossref","first-page":"e0239675","DOI":"10.1371\/journal.pone.0239675","article-title":"Screening for Fabry disease in patients with unexplained left ventricular hypertrophy","volume":"15","author":"Sadasivan","year":"2020","journal-title":"PLoS One"},{"key":"2024042116171078000_ehae148-B107","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41591-018-0240-2","article-title":"Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram","volume":"25","author":"Attia","year":"2019","journal-title":"Nat Med"},{"key":"2024042116171078000_ehae148-B108","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jacc.2019.12.030","article-title":"Detection of hypertrophic cardiomyopathy using a convolutional neural network-enabled electrocardiogram","volume":"75","author":"Ko","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024042116171078000_ehae148-B109","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2021.06.021","article-title":"Artificial intelligence-enabled electrocardiography to screen patients with dilated cardiomyopathy","volume":"155","author":"Shrivastava","year":"2021","journal-title":"Am J Cardiol"},{"key":"2024042116171078000_ehae148-B110","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.mayocp.2021.04.023","article-title":"Artificial intelligence-enhanced electrocardiogram for the early detection of cardiac amyloidosis","volume":"96","author":"Grogan","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2024042116171078000_ehae148-B111","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/j.jacc.2016.08.062","article-title":"Machine-learning algorithms to automate morphological and functional assessments in 2D echocardiography","volume":"68","author":"Narula","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2024042116171078000_ehae148-B112","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.118.034338","article-title":"Fully automated echocardiogram interpretation in clinical practice: feasibility and diagnostic accuracy","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"2024042116171078000_ehae148-B113","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamacardio.2021.6059","article-title":"High-throughput precision phenotyping of left ventricular hypertrophy with cardiovascular deep learning","volume":"7","author":"Duffy","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2024042116171078000_ehae148-B114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-70551-8","article-title":"CINENet: deep learning-based 3D cardiac CINE MRI reconstruction with multi-coil complex-valued 4D spatio-temporal convolutions","volume":"10","author":"K\u00fcstner","year":"2020","journal-title":"Sci Rep"},{"key":"2024042116171078000_ehae148-B115","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jcmg.2021.08.011","article-title":"AI based CMR assessment of biventricular function: clinical significance of intervendor variability and measurement errors","volume":"15","author":"Wang","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"2024042116171078000_ehae148-B116","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1161\/CIRCULATIONAHA.122.060137","article-title":"Artificial intelligence for contrast-free MRI: scar assessment in myocardial infarction using deep learning-based virtual native enhancement","volume":"146","author":"Zhang","year":"2022","journal-title":"Circulation"},{"key":"2024042116171078000_ehae148-B117","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s13023-021-02150-3","article-title":"A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm","volume":"16","author":"Jefferies","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"2024042116171078000_ehae148-B118","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/s41588-023-01465-0","article-title":"Genome-wide prediction of disease variant effects with a deep protein language model","volume":"55","author":"Brandes","year":"2023","journal-title":"Nat Genet"},{"key":"2024042116171078000_ehae148-B119","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2024042116171078000_ehae148-B120","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2024042116171078000_ehae148-B121","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.3390\/jcm12113689","article-title":"Dapaglifozin on albuminuria in chronic kidney disease patients with Fabry disease: the DEFY study design and protocol","volume":"12","author":"Battaglia","year":"2023","journal-title":"J Clin Med"},{"key":"2024042116171078000_ehae148-B122","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur Heart J"},{"key":"2024042116171078000_ehae148-B123","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1136\/heartjnl-2019-315229","article-title":"Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy","volume":"105","author":"Vijapurapu","year":"2019","journal-title":"Heart"},{"key":"2024042116171078000_ehae148-B124","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in Fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol Genet Metab"},{"key":"2024042116171078000_ehae148-B125","doi-asserted-by":"crossref","first-page":"1024963","DOI":"10.3389\/fimmu.2022.1024963","article-title":"Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease","volume":"13","author":"Lenders","year":"2022","journal-title":"Front Immunol"},{"key":"2024042116171078000_ehae148-B126","doi-asserted-by":"crossref","first-page":"104641","DOI":"10.1016\/j.cellimm.2022.104641","article-title":"Oral tolerance to prevent anti-drug antibody formation in protein replacement therapies","volume":"382","author":"Rana","year":"2022","journal-title":"Cell Immunol"},{"key":"2024042116171078000_ehae148-B127","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/joim.12647","article-title":"Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease","volume":"282","author":"Lenders","year":"2017","journal-title":"J Intern Med"},{"key":"2024042116171078000_ehae148-B128","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","article-title":"Treatment of Fabry disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)","volume":"8","author":"Lenders","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024042116171078000_ehae148-B129","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/hmg\/ddad073","article-title":"Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease","volume":"32","author":"Nikolaenko","year":"2023","journal-title":"Hum Mol Genet"},{"key":"2024042116171078000_ehae148-B130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00441-023-03821-2","article-title":"Beyond animal models: revolutionizing neurodegenerative disease modeling using 3D in vitro organoids, microfluidic chips, and bioprinting","volume":"294","author":"Teli","year":"2023","journal-title":"Cell Tissue Res"},{"key":"2024042116171078000_ehae148-B131","doi-asserted-by":"crossref","first-page":"103540","DOI":"10.1016\/j.mcn.2020.103540","article-title":"Role of induced pluripotent stem cells in lysosomal storage diseases","volume":"108","author":"Kido","year":"2020","journal-title":"Mol Cell Neurosci"},{"key":"2024042116171078000_ehae148-B132","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12967-023-03992-0","article-title":"Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid system","volume":"21","author":"Cui","year":"2023","journal-title":"J Transl Med"},{"key":"2024042116171078000_ehae148-B133","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.122.320305","article-title":"Cellular and engineered organoids for cardiovascular models","volume":"130","author":"Thomas","year":"2022","journal-title":"Circ Res"},{"key":"2024042116171078000_ehae148-B134","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/s41563-023-01611-3","article-title":"Fibre-infused gel scaffolds guide cardiomyocyte alignment in 3D-printed ventricles","volume":"22","author":"Choi","year":"2023","journal-title":"Nat Mater"},{"key":"2024042116171078000_ehae148-B135","author":"US Food and Drug Administration"},{"key":"2024042116171078000_ehae148-B136","doi-asserted-by":"crossref","first-page":"100824","DOI":"10.1016\/j.ymgmr.2021.100824","article-title":"Patient-reported outcome (FD-PRO) demonstrates robust measurement properties for assessing symptom severity in Fabry disease","volume":"29","author":"Hamed","year":"2021","journal-title":"Mol Genet Metab Rep"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/16\/1395\/57296230\/ehae148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/16\/1395\/57296230\/ehae148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T06:48:56Z","timestamp":1731480536000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/45\/16\/1395\/7629175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":136,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,3,15]]},"published-print":{"date-parts":[[2024,4,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae148","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,21]]},"published":{"date-parts":[[2024,3,15]]}}}